Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779831 | 1.00 | MAPT (0.58) | MAPTRAB9ANPC1APPFBP1 | |
| SCHEMBL9170800 | 0.77 | APP (0.78) | MAPTRAB9ANPC1APPFBP1 | |
| SCHEMBL9170804 | 0.77 | APP (0.78) | MAPTRAB9ANPC1APPFBP1 | |
| SCHEMBL14947048 | 0.77 | APP (0.78) | MAPTRAB9ANPC1APPFBP1 | |
| SCHEMBL458177 | 0.77 | APP (0.78) | MAPTRAB9ANPC1APPFBP1 | |
| SCHEMBL458178 | 0.77 | APP (0.78) | MAPTRAB9ANPC1APPFBP1 | |
| SCHEMBL6610065 | 0.75 | GAA (0.47) | MAPTRAB9ANPC1APPMEN1 | |
| SCHEMBL5779809 | 0.75 | CYP19A1 (0.45) | MAPTRAB9ANPC1APPCYP19A1 | |
| SCHEMBL6610070 | 0.75 | GAA (0.47) | MAPTRAB9ANPC1APPMEN1 | |
| SCHEMBL62411 | 0.74 | MAPT (1.00) | MAPTRAB9ANPC1APPFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | MAPT 94/4885RAB9A 3127/4885NPC1 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.